Furthermore, the preferential overexpression of HLA-E/β2m in metastases associated with CD94+ TILs, provides supplementary convincing arguments to inhibit this new immune checkpoint NKG2A with monalizumab, in combination with anti- FcγRIIIA/EGFR bispecific antibodies as a promising therapeutic perspective in RAS wild-type mCRC patients to improve both ADCC and anti-tumor T cell responses. Here, FCGR3A is linked to neoplasm.